• 1. Emergence of cationic polyamine dendrimersomes: design, stimuli sensitivity and potential biomedical applications
  Partha Laskar,Christine Dufès Nanoscale Adv., 2021,3, 6007-6026
• 2. Embedding heteroatoms: an effective approach to create porphyrin-based functional materials
  Norihito Fukui,Keisuke Fujimoto,Hideki Yorimitsu,Atsuhiro Osuka Dalton Trans., 2017,46, 13322-13341
• 3. Enantiocontrolled construction of sistodiolynne, an unusual polyketide from the wood-decay fungus Sistrema raduloides
  Chem. Commun., 1997, 767-768
• 4. Examination of the hydrogen-bonding networks in small water clusters (n = 2–5, 13, 17) using absolutely localized molecular orbital energy decomposition analysis?
  Erika A. Cobar,Paul R. Horn,Robert G. Bergman,Martin Head-Gordon Phys. Chem. Chem. Phys., 2012,14, 15328-15339
• 5. Evolution study of photo-synthesized gold nanoparticles by spectral deconvolution model: a quantitative approach
  Chung-Sung Yang,Mong-Shian Shih,Fang-Yi Chang New J. Chem., 2006,30, 729-735

Introduction to 8-oxo-7-azaspiro[3.5]nonane-5-carboxylic acid (CAS No. 2098142-54-0)

8-oxo-7-azaspiro[3.5]nonane-5-carboxylic acid, identified by the chemical compound code CAS No. 2098142-54-0, is a sophisticated heterocyclic compound that has garnered significant attention in the field of medicinal chemistry and pharmacology. This compound belongs to the spirocyclic class of molecules, characterized by a unique structural framework where two rings are joined together at one or more common atoms. The presence of both an oxo group and an azaspiro core imparts distinct electronic and steric properties, making it a promising candidate for various biochemical applications.

The molecular structure of 8-oxo-7-azaspiro[3.5]nonane-5-carboxylic acid consists of a nine-membered spirocyclic ring system, which is a critical feature for its biological activity. The carboxylic acid functionality at the 5-position provides a site for further chemical modifications, enabling the synthesis of derivatives with enhanced pharmacological properties. This structural motif has been extensively studied for its potential in modulating enzyme activity, particularly in the context of kinases and other signal transduction pathways.

In recent years, there has been a surge in research focusing on spirocyclic compounds due to their unique conformational rigidity and ability to mimic natural substrates or inhibitors. The 7-azaspiro core in 8-oxo-7-azaspiro[3.5]nonane-5-carboxylic acid has been shown to exhibit high binding affinity to biological targets, making it an attractive scaffold for drug discovery. Studies have demonstrated that such spirocyclic structures can effectively interfere with the binding of ATP to protein kinases, thereby inhibiting their activity.

One of the most compelling aspects of 8-oxo-7-azaspiro[3.5]nonane-5-carboxylic acid is its potential application in oncology research. Kinase inhibitors are a cornerstone of modern cancer therapy, and compounds with spirocyclic motifs have shown promise in preclinical studies as potent inhibitors of aberrantly activated kinases involved in tumor growth and progression. The oxo group within the molecule contributes to its ability to engage with hydrophobic pockets within the kinase active site, enhancing its inhibitory efficacy.

The synthesis of 8-oxo-7-azaspiro[3.5]nonane-5-carboxylic acid involves multi-step organic reactions that require precise control over reaction conditions to ensure high yield and purity. Advanced synthetic methodologies, including transition-metal-catalyzed reactions and asymmetric synthesis techniques, have been employed to construct the spirocyclic core efficiently. These synthetic strategies not only facilitate the production of the compound but also allow for structural diversification, enabling the exploration of novel derivatives with tailored biological activities.

Recent advancements in computational chemistry have further accelerated the discovery process for compounds like 8-oxo-7-azaspiro[3.5]nonane-5-carboxylic acid. Molecular modeling studies have been instrumental in predicting binding interactions between this compound and its target proteins, providing insights into its mechanism of action. These computational approaches complement experimental efforts by allowing researchers to screen large libraries of analogs virtual before synthesizing them, thereby optimizing drug design pipelines.

The pharmacokinetic profile of 8-oxo-7-azaspiro[3.5]nonane-5-carboxylic acid is another area of active investigation. Understanding how this compound is metabolized and eliminated by the body is crucial for developing effective therapeutic regimens. Preliminary studies suggest that the spirocyclic structure imparts favorable solubility properties, which could enhance oral bioavailability—a critical factor for drug efficacy and patient compliance.

In conclusion, 8-oxo-7-azaspiro[3.5]nonane-5-carboxylic acid (CAS No. 2098142-54-0) represents a significant advancement in medicinal chemistry due to its unique structural features and promising biological activities. Its spirocyclic framework, combined with functional groups such as the carboxylic acid and oxo moieties, makes it an ideal candidate for further exploration in drug discovery programs targeting kinases and other therapeutic targets. As research continues to uncover new applications for this compound, it is likely to play an increasingly important role in developing next-generation pharmaceuticals.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)